

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Mail Stop RCE, Hon. Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 29th day October of 2004

By

(Signature of person mailing)

Madeline Deveran

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: David B. MacLean :

APPLICATION NO.: 09/995,130 : Examiner: Shengjun Wang

FILING DATE: November 27, 2001 : Group Art Unit: 1617

TITLE: THERAPY FOR ANDROPAUSE USING :
ESTROGEN AGONISTS/ANTAGONISTS
AND TESTOSTERONE

Hon. Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.


It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date: 28 OCTOBER 2004

Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 715-4331


John A. Wichtowski
Attorney for Applicant(s)
Reg. No. 48,032

